Patients fully understand the study, voluntarily participate in and sign on the informed consent;
Diagnosed by histopathology Peripheral T-cell lymphoma;
ECOG PS score 0 or 1;
Relapsed or Refractory Peripheral T Cell Lymphoma;
According to the 2014 version of the Lugano criteria for lymphoma, there must be at least one CT/MRI measurable lesion (measurable lymph node diameter\>1.5cm; measurable extranodal lesion diameter\>1.0cm);
Provided a written pathological/histological diagnosis report during the screening period and agreed to provide tumor tissue sections or tumor/lymph node tissue specimens for testing at the central laboratory;
Expected survival at least 12 weeks;
Agreed to receive treatment with Pralatrexate
You may not be if
NK/T-cell lymphoma;
Achieving CR or PR after induction chemotherapies without relapse;
Dysfunction of vital organs;
Serious history of autoimmune diseases and immunodeficiency, including: positive for human immunodeficiency virus (HIV) antibodies; Or other acquired or congenital immunodeficiency diseases; Or have a history of organ transplantation;
Unwilling to accept allogeneic hematopoietic stem cell transplantation;
Undergoing other clinical studies within a month;
Without donor for transplantation;
Allergies to similar drugs and excipients of the research drug